(Press-News.org) In a large, international, randomized trial, initial radiotherapy was compared to temozolomide chemotherapy. A statistically significant difference between the two treatment strategies was not observed for progression-free survival, although radiotherapy was numerically favored. However, molecular tumor characterization may allow the treatment approach to be personalized and one or the other treatment modality to be selected.
The results of EORTC trial 22033-26033 will be presented Saturday, 01 June 2013 at an ASCO 2013 Oral Abstract Session by the coordinator of the study Brigitta Baumert, MD, PhD of the Radiation Oncology Department, Maastricht University (MAASTRO) and recently appointed deputy head of the Radiotherapy Department of the MediClin Robert-Janker Clinic, Clinical Cooperation Unit Neurooncology & University of Bonn Medical Center, Germany. In this trial, 477 patients from 18 countries were randomized (after molecular stratification for 1p-status) between radiotherapy (240 patients) and chemotherapy with temozolomide (237 patients), a drug which has been shown to have an activity in low-grade glioma. The trial results show that first line treatment with temozolomide compared to radiotherapy does not improve progression-free survival in these high-risk low grade glioma patients.
Dr. Baumert states, "This is the first study in primary brain tumor to prospectively evaluate molecular markers. In the future, diagnosis of low-grade glioma will be substituted by a more differentiated molecular tumor characterization upon which treatment strategies will depend. The data are preliminary – as median overall survival has not yet been reached. Good wine needs aging…"
Outcome for patients with low-grade glioma varies widely. In previous randomized trials the EORTC and others have shown that treatment can be deferred in patients without additional risk factors. For higher risk patients, radiotherapy might be of value. EORTC trial 22033-26033 was designed for patients with a prognostic profile that indicated a poor outcome and investigated whether primary chemotherapy as compared to standard radiotherapy would prolong progression-free and overall survival.
The study also sought to identify prognostic molecular factors that might assist in making treatment decisions. At the time of study conception, the prognostic importance for tumor response to treatment in the presence of a chromosomal deletion on the short arm of chromosome 1 was known, and consequently patients were stratified before randomization. Other markers will be analyzed now that the study is complete and will clarify why some patients have a much better disease evolution than others.
"This is a very important study in our quest to personalize treatment strategies. The ongoing molecular tumor characterization will identify individual characteristics guiding future treatment decisions – be it intensifying therapy for some, or withholding therapy for others", said Roger Stupp, Director of the Zurich University Cancer Center, President of the EORTC and one of the Principal Investigators of the study.
At a median follow-up of 45.5 months and after the tumors of 246 patients had progressed, there was no statistical difference in progression-free survival, the primary endpoint. Overall toxicity was mild. Grade 3 hematological toxicity was observed in 9% of the temozolomide treated patients.
Secondary analyses included overall survival and the impact of 1p status. Median overall survival is not yet reached, but 1p deletion was confirmed to be a positive prognostic factor with either treatments (p-value stratified by treatment, progression-free survival: p = 0.0003; HR = 0.59, 95% CI (0.45 - 0.78), overall survival: p = 0.002; HR = 0.49, 95% CI (0.32 - 0.77)). Although the interaction test was not significant, for patients treated with temozolomide, there was a trend for inferior progression-free survival in patients who had 1p intact, and overall survival may be better for patients who had the 1p deletion. The survival analyses require further maturation and more molecular data (1p/19q, IDH1 etc.) to further characterize the responders to temozolomide therapy and guide treatment decision. Analyses of molecular profiles, neurocognition and quality-of-life are ongoing.
###
This Intergroup trial was coordinated by the EORTC Radiation Oncology and Brain Tumor Groups in collaboration with Medical Research Council Clinical Trial Unit in the United Kingdom, the National Cancer Institute of Canada Clinical Trial Group, and Trans-Tasman Radiation Oncology Group in Australia. It was supported by an unrestricted educational grant and drug by MSD-Merck&Co, and by grant numbers 5U10 CA011488-35 through 5U10 CA011488-41 from the National Cancer Institute of the United States.
For more information concerning EORTC trial 22033-26033 please contact: http://www.eortc.org/contact
About the EORTC
The European Organisation for the Research and Treatment of Cancer (EORTC) brings together European cancer clinical research experts from all disciplines for trans-national collaboration.
Both multinational and multidisciplinary, the EORTC Network comprises more than 2,500 collaborators from all disciplines involved in cancer treatment and research in more than 300 hospitals in over 30 countries.
Through translational and clinical research, the EORTC offers an integrated approach to drug development, drug evaluation programs and medical practices.
EORTC Headquarters, a unique pan European independent clinical research infrastructure, is based in Brussels, Belgium, from where its various activities are coordinated and run.
http://www.eortc.org/contact
Radiotherapy remains the treatment of first choice for high-risk low-grade glioma
Results of EORTC trial 22033-26033 presented at ASCO 2013
2013-05-29
ELSE PRESS RELEASES FROM THIS DATE:
Is YouTube an effective research tool?
2013-05-29
New Rochelle, NY, May 29, 2013—YouTube has more than 10 million unique users a month who are younger than 18 years of age, making it an ideal online environment in which to study the impact of various media content and peer feedback on adolescents. A series of experiments were designed to test the effectiveness of using YouTube to present controlled media content and peer comments to teens, and to measure their preferences and moral judgments. The results are presented in Cyberpsychology, Behavior, and Social Networking, a peer-reviewed journal from Mary Ann Liebert, Inc., ...
Human scabs serve as inspiration for new bandage to speed healing
2013-05-29
Human scabs have become the model for development of an advanced wound dressing material that shows promise for speeding the healing process, scientists are reporting. Their study appears in the journal ACS Applied Materials & Interfaces.
Shutao Wang and colleagues explain that scabs are a perfect natural dressing material for wounds. In addition to preventing further bleeding, scabs protect against infection and recruit the new cells needed for healing. Existing bandages and other dressings for wounds generally are intended to prevent bleeding and infections. Wang's ...
EORTC study identifies patients with anaplastic oligodendroglioma that benefit from adjuvant PCV
2013-05-29
A further report on the results of EORTC trial 26951 indicates that CpG island methylator phenotype (CIMP) status and O 6-methylguanine-DNA methyltransferase (MGMT) promoter methylation as assessed by MGMT-STP27 are the most informative for identifying grade III glioma patients who might benefit from the addition of procarbazine, CCNU and vincristine (PCV) chemotherapy to radiation therapy. Prior results had shown that PCV chemotherapy following standard radiation therapy delayed tumor growth and extended the lives of patients with anaplastic oligodendroglial tumors, a ...
Charred micro-bunny sculpture shows promise of new material for 3-D shaping
2013-05-29
Though its surface has been turned to carbon, the bunny-like features can still be easily observed with a microscope. This rabbit sculpture, the size of a typical bacterium, is one of several whimsical shapes created by a team of Japanese scientists using a new material that can be molded into complex, highly conductive 3-D structures with features just a few micrometers across. Combined with state-of-the-art micro-sculpting techniques, the new resin holds promise for making customized electrodes for fuel cells or batteries, as well as biosensor interfaces for medical uses. ...
Despite safety and other concerns, nuclear power saves lives, greenhouse gas emissions
2013-05-29
Global use of nuclear power has prevented about 1.84 million air pollution-related deaths and release of 64 billion tons of greenhouse gases that would have resulted from burning coal and other fossil fuels, a new study concludes. It appears in the ACS journal Environmental Science & Technology.
Pushker A. Kharecha and James E. Hansen state that nuclear power has the potential to help control both global climate change and illness and death associated with air pollution. That potential exists, they say, despite serious questions about safety, disposal of radioactive waste ...
A new addition to the Hall of Fame of science venues
2013-05-29
A building that helped launch generations of scientists, including Nobel laureates, on their careers of discovery has joined the Hall of Fame of notable venues, being named a National Historic Chemical Landmark by the American Chemical Society (ACS).
That's the topic of an article in the current edition of Chemical & Engineering News (C&EN), the weekly newsmagazine of the ACS, the world's largest scientific society.
Susan J. Ainsworth, C&EN senior editor, explains that the ACS recognized the R.B. Wetherill Laboratory of Chemistry building on the Purdue University's ...
New Mayo Clinic approach could lead to blood test to diagnose Alzheimer's in earliest stage
2013-05-29
ROCHESTER, Minn. -- Blood offers promise as a way to detect Alzheimer's disease at its earliest onset, Mayo Clinic researchers say. They envision a test that would detect distinct metabolic signatures in blood plasma that are synonymous with the disease -- years before patients begin showing cognitive decline. Their study was recently published online in the journal PLOS ONE.
Researchers analyzed cerebrospinal fluid and plasma samples from 45 people in the Mayo Clinic Study on Aging and Mayo Clinic Alzheimer's Disease Center (15 with no cognitive decline, 15 with mild ...
Study shows longer treatment for children with langerhans cell hystiocytosis improves survival rates
2013-05-29
Washington, DC—A new international study finds that prolonged, intense initial treatment in children with multi-system Langerhans cell histiocytosis (MS-LCH) can achieve survival rates as high as 84 percent—a full 15 percent improvement over the previous clinical trial in this series.
The study, LCH-III, is published in Blood, the journal of the American Society of Hematology. It is the third in a series of international randomized clinical trials for LCH that spans twenty years initiated and coordinated by the Histiocyte Society, a group of more than 200 physicians and ...
Twitter may become less interactive and more an advertising broadcast medium like TV or radio
2013-05-29
PITTSBURGH—Popular social media site Twitter may eventually resemble a broadcast medium like television or radio, with users reading messages written by celebrities and corporations rather than writing their own "tweet" messages of up to 140 characters, suggests a new study coauthored by Andrew T. Stephen, assistant professor of business administration and Katz Fellow in Marketing in the University of Pittsburgh's Joseph M. Katz Graduate School of Business and College of Business Administration.
In one of the first studies to use social media as a laboratory for social ...
People can 'beat' guilt detection tests by suppressing incriminating memories
2013-05-29
New research published by an international team of psychologists has shown that people can suppress incriminating memories and thereby avoid detection in brain activity guilt detection tests.
Such tests, which are commercially available in the USA and are used by law enforcement agencies in several countries, including Japan and India, are based on the logic that criminals will have specific memories of their crime stored in their brain. Once presented with reminders of their crime in a guilt detection test, it is assumed that their brain will automatically and uncontrollably ...
LAST 30 PRESS RELEASES:
New strategies to enhance chiral optical signals unveiled
Cambridge research uncovers powerful virtual reality treatment for speech anxiety
2025 Gut Microbiota for Health World Summit to spotlight groundbreaking research
International survey finds that support for climate interventions is tied to being hopeful and worried about climate change
Cambridge scientist launches free VR platform that eliminates the fear of public speaking
Open-Source AI matches top proprietary model in solving tough medical cases
Good fences make good neighbors (with carnivores)
NRG Oncology trial supports radiotherapy alone following radical hysterectomy should remain the standard of care for early-stage, intermediate-risk cervical cancer
Introducing our new cohort of AGA Future Leaders
Sharks are dying at alarming rates, mostly due to fishing. Retention bans may help
Engineering excellence: Engineers with ONR ties elected to renowned scientific academy
New CRISPR-based diagnostic test detects pathogens in blood without amplification
Immunotherapy may boost KRAS-targeted therapy in pancreatic cancer
Growing solar: Optimizing agrivoltaic systems for crops and clean energy
Scientists discover how to reactivate cancer’s molecular “kill switch”
YouTube influencers: gaming’s best friend or worst enemy?
uOttawa scientists use light to unlock secret of atoms
NJIT mathematician to help map Earth's last frontier with Navy grant
NASA atmospheric wave-studying mission releases data from first 3,000 orbits
‘Microlightning’ in water droplets may have sparked life on Earth
Smoke from wildland-urban interface fires more deadly than remote wildfires
What’s your body really worth? New AI model reveals your true biological age from 5 drops of blood
Protein accidentally lassos itself, helping explain unusual refolding behavior
With bird flu in raw milk, many in U.S. still do not know risks of consuming it
University of Minnesota research team awarded $3.8 million grant to develop cell therapy to combat Alzheimer’s disease
UConn uncovers new clue on what is leading to neurodegenerative diseases like Alzheimer’s and ALS
Resuscitation in out-of-hospital cardiac arrest – it’s how quickly it is done, rather than who does it
A closer look at biomolecular ‘silly putty’
Oxytocin system of breastfeeding affected in mothers with postnatal depression
Liquid metal-enabled synergetic cooling and charging: a leap forward for electric vehicles
[Press-News.org] Radiotherapy remains the treatment of first choice for high-risk low-grade gliomaResults of EORTC trial 22033-26033 presented at ASCO 2013